Suven Life Sciences Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript pages. - The focus appears to be on securing raw material supply, progressing clinical trials, and CAPEX spending rather than raising funds. - The company has planned CAPEX of Rs. 270 crore over 18 months, funded likely from internal resources or existing mechanisms; no mention of raising funds externally. - Research and development expenses and clinical trial costs are being managed within existing budgets without indications of new fundraising. - Out-licensing of the molecule SUVN-502 is considered a potential future monetization path, but no fundraising is planned related to this as of now.

- Planned CAPEX of Rs. 270 crore, with Rs. 70 crore already spent. - Additional Rs. 200 crore to be spent within the next 18 months (covering FY2019 and FY2020). - A significant portion (Rs. 120 crore) is allocated for constructing a new block with occupational exposure levels required for new CRAMS projects. - This CAPEX aims to meet future customer requirements and secure capacity for new and existing projects. - The new block investment can potentially be recovered within 18 months if orders are secured quickly, although it could take 2-3 years. - Efforts toward backward integration of raw materials are ongoing but are limited in scale due to cost-effectiveness. - Capacity utilization is currently at 100%.

- The core CRAMS business is in a growth phase and expected to grow around 10%-15% yearly. - Growth depends heavily on the success and progression of clinical trials for molecules in development. - There is an emphasis on transitioning molecules from Phase-1 to Phase-2 and later to Phase-3, with more activity expected from Phase-2 to Phase-3 over time. - The number of molecules in development has been reduced, focusing on fewer but more promising candidates, leading to better traction and continuation through clinical phases. - The company expects stability within next two to four quarters by securing raw material supplies despite current shortages. - Specialty CRAMS business is expected to remain flat, growing around 5%. - Commercial product revenues are anticipated to be around Rs. 60-90 crore yearly. - Out-licensing opportunities depend on positive clinical trial data, potentially driving significant growth.

- The core CRAMS business is expected to grow in the range of 10% to 15% annually. - Specialty segment growth is expected to be flat, with a variance of around 5% compared to the previous year. - The CRAMS business growth depends heavily on the success of clinical trials, with progression from Phase-1 to Phase-2 currently active and Phase-2 to Phase-3 expected to pick up gradually. - Raw material supply issues impacted revenue and profits in the short term but are expected to stabilize within two to three quarters. - Overall earnings and profits face variability due to clinical trial outcomes and raw material availability. - Consolidated financials may see pressure due to increasing clinical trial costs, but standalone business aims to maintain last year's earnings. - Out-licensing of successful molecules like SUVN-502 after positive clinical data can drive significant monetization, projected around Q3 of the following year (FY2020).

- As of the latest quarter discussed, Suven Life Sciences reports having a total of 116 CRAMS projects. - Compared to the previous quarter (June 2018) and September 2017, there has been a net addition of 1 project recently, with 5 new projects added and 4 projects completed. - The current base CRAMS business is expected to grow at a rate of 10% to 15% annually. - Raw material shortages have caused some delays, but the company has secured raw material for shipments for the next two quarters. - There might be potential delays after the next two quarters due to raw material sourcing challenges, but efforts for backward integration and alternate sourcing are underway. - The company is confident about maintaining a stable order flow, with expectations that disruptions due to raw material shortages will ease within three to four quarters.